20 articles
A Lancet Healthy Longevity editorial calls for systemic elevation of cancer survivorship care as a public health and longevity priority.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
Large study reveals cancer survivors have higher biological age than cancer-free individuals, with strongest mortality predictions from epigenetic clocks.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
New research reveals young and elderly cervical cancer patients have completely different molecular signatures requiring age-specific treatments.
Study identifies blood markers that distinguish long-term survivors from short-term survivors in brain cancer treatment.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
New study reveals optimal timing strategy for combining radiation and immunotherapy treatments in advanced lung cancer patients.
Specific mutational signatures accumulate linearly with age in normal tissues, offering a new window into why cancer risk rises exponentially as we get older.
Rare genetic syndrome caused by TP53 mutations leads to extraordinarily high lifetime cancer risk, with new prevention strategies emerging.
Study of 183 brain tumor samples reveals distinct telomere maintenance patterns that could guide personalized cancer therapy.
New review reveals how senescent cells both prevent and promote cancer, opening therapeutic opportunities.
ASTER 70s trial compares treatment intensities for women 70+ with genomically high-risk breast cancer to optimize outcomes while minimizing toxicity.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
New patient-centered outcome measure tracks meaningful recovery time at home after spinal metastases treatment.
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
Dive deep into the molecular machinery of genomic instability — from telomere-driven crisis states and epigenetic remodeling at break sites to cutting-edge therapeutic strategies targeting DNA repair fidelity in aging and cancer.
